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Zhonghu Li†, Kai Chen†, Peng Jiang, Xi Zhang, Xiaowu Li* and Zhihua Li*Abstract
Background and purpose: CD44 variants have been associated with tumor invasion and metastasis, but CD44
expression patterns have not been systematically investigated in pancreatic carcinoma. This study systematically
investigated whether CD44 expression patterns are involved in pancreatic carcinoma metastasis and prognosis.
Methods: We applied primers specific for all CD44 variants and CD44s to analyze the expression patterns of CD44
(CD44v2-CD44v10 and CD44s) using quantitative real-time PCR (qRT-PCR). We then further evaluated their roles in
pancreatic carcinoma metastasis and prognosis using clinical survival analysis.
Results: Increased CD44v expression and decreased CD44s expression were found in metastatic pancreatic carcinoma
in three different cell lines and in human tumor tissue. Clinical analysis showed that CD44v6+ and CD44v9+ were
correlated with lymph node metastasis, liver metastasis and TNM stage. However, CD44s− was associated with liver
metastasis, tumor differentiation and TNM stage. Survival analysis showed that patients with CD44v6+/CD44s− or
CD44v6+/CD44s− had lower overall survival (OS) rates, although the individual expression of CD44v6, CD44v9 and
CD44s was also related to decreased OS rates. Univariate analysis showed that lymph node metastasis; vessel invasion;
hepatic metastases; TNM stage; and individual or co-expression of CD44v6, CD44v9 and CD44s were risk factors
affecting survival. Multivariate analysis showed that CD44v6+/CD44s− was an independent predictor of survival.
Conclusions: We found that CD44v6+, CD44v9+ and CD44s− were associated with pancreatic carcinoma metastasis
and progression and that CD44v6+/CD44s− was an independent risk factor affecting survival in pancreatic carcinoma.
Therefore, the different expression patterns of CD44v/CD44s may determine pancreatic carcinoma prognosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1579257224116287.
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Pancreatic carcinoma (PCa) is undoubtedly the most
aggressive and the deadliest cancer [1]. Early metastasis
to regional lymph nodes or hematogenous spread to dis-
tant organs is largely responsible for the lowest 5-year
survival rate (less than 5%) [2,3]. Numerous molecules
have been described and extensively investigated for
their potential roles in the tumorigenesis and progres-
sion of PCa; CD44 is the most important of these
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unless otherwise stated.CD44 is quite complicated. This molecule is encoded
by 20 exons and undergoes extensive alternative splicing
to generate CD44s (CD44 standard) and CD44v (CD44
variants) [4-6]. CD44s consists of exons 1–5 and 16–20
and is called the constant form. The variable exons are
typically numbered v1-v10 (v1 is not encoded in humans),
corresponding to the genomic exons 6–15, and are alter-
natively spliced and incorporated into the variable region
either singly or in combination. This process has the po-
tential to generate thousands of different CD44 isoforms
(Additional file 1: Figure S1) [6-8], and as a result, CD44
has complex and diverse functions.
CD44 was initially identified as a lymphocyte homing
receptor and transmembrane glycoprotein [4,9] com-
monly expressed in embryonic stem cells [10] and inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CD44 plays an important role in many cell processes,
including growth, differentiation and motility [14], there
are discrepancies in the literature about the roles of
CD44v and CD44s in tumor progression. In certain can-
cers, CD44s and CD44v are considered to be tumor pro-
gression promoters [15-27], but in other cancers, CD44s
and CD44v may be involved in tumor suppression
[28-39]. These discrepancies may be the result of differ-
ent methods for detecting CD44 (such as immunohisto-
chemistry (IHC) or PCR) and identifying different CD44
variants in different tumor types. The roles of CD44 in
PCa are still disputed. Tsukuda, H [40] reported that
CD44v6 and CD44v2 were expressed in the pancreatic
juice of patients with pancreatic carcinoma, but the
authors also reported CD44v expression in normal cases.
Rall, C. J. [41] studied CD44 expression in 21 clinical PCa
tissues and reported the expression of CD44v6, CD44v8-9,
CD44v8-10 and CD44s, although only CD44v6 may be
involved in tumor metastasis. Tomaszewska, R [42] re-
ported that CD44v6 and CD44s expression was positive in
pancreatic carcinoma, and Gotoda, T. et al. [43] reported
that CD44v6 and CD44v2 may be useful markers for poor
survival after studying the expression of CD44v6, CD44v2
and CD44s via IHC. However, all studies found no signifi-
cant association between CD44s and tumor progression.
In fact, the expression patterns of CD44 in pancreatic
carcinoma have not been systematically investigated at the
mRNA level. To investigate whether CD44 expression pat-
terns are related to pancreatic carcinoma metastasis and
prognosis, we designed a primer specific for each CD44
variant (CD44v2-CD44v10 and CD44s), detected the
expression patterns of CD44 in 101 clinical pancreatic
carcinoma samples, and analyzed the relationship of




A total of 101 patients underwent surgery for pancreatic
carcinoma at the Department of Hepatobiliary Surgery
Institute, Southwest Hospital, Third Military Medical
University, China, from January 2008 to January 2010.
All patients underwent curative resection by pancreati-
coduodenectomy or pylorus-preserving pancreaticoduo-
denectomy with lymph node dissection. None of the
patients received neoadjuvant or adjuvant radio/chemo-
therapy. All 101 tumor samples were cryopreserved in
liquid nitrogen at the time of excision to facilitate RNA
extraction and quantitative real-time PCR (qRT-PCR)
analysis. The patient characteristics are shown in Table 1.
All patients were followed up by radiography, ultrasonog-
raphy and computed tomography every 3 months after
discharge. The median follow-up period was 12 months(range 4–46 months), and during this period, 10 patients
were found to have liver metastases, and 1 patient was
found to have lung metastases.
This study was approved by the Ethics Committee of
Southwest Hospital, and all patients provided written
informed consent.
Cell culture
The Aspc-1, Cfpac-1 and Panc-1 pancreatic carcinoma
cell lines were purchased from the Shanghai Biomedical
Institute. The Cfpac-1 and Panc-1 cell lines were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM;
HyClone, Thermo, USA), and the Aspc-1 cell line was
maintained in Roswell Park Memorial Institute 1640
medium (1640; HyClone, Thermo, USA). All cell cultures
were supplemented with 10% fetal bovine serum (FBS;
GIBCO/Invitrogen, CA, USA) in the presence of 100 U/
ml penicillin and 100 mg/ml streptomycin. All cell lines
were cultured at 37°C in a humidified atmosphere con-
taining 5% CO2.
Cell invasion assay
To perform invasion assays, 5 × 105 cells in 300 μL serum-
free medium were placed in the upper chamber (Millipore,
MA, USA) of an insert coated with 30 μL Matrigel (BD,
Franklin Lakes, USA), and 600 μL medium (DMEM or
1640) containing 10% FBS was added to the lower cham-
ber. After a 24-hour incubation, the cells remaining on the
upper membrane were removed with cotton wool. The
cells that had passed through the membrane were stained
with hematoxylin, imaged using a BX41 microscope
(Olympus, Tokyo, Japan) and counted in 10 fields per well
at 200x magnification using a CKX41 inverted microscope
(Olympus, Tokyo, Japan). The experiments were inde-
pendently repeated three times.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissues or cultured cells
using RNAiso Plus reagent (TaKaRa, Dalian, China) ac-
cording to the manufacturer’s protocol. The RNA was
stored at −80°C, and reverse transcription (RT) of the
extracted RNA was performed using the PrimeScript RT
reagent Kit with gDNA Eraser (TaKaRa, Dalian, China).
The cDNA was stored at −20°C. qRT-PCR assays were
performed to detect CD44 expression using the Prime-
Script RT reagent Kit and SYBR Premix Ex Taq (TaKaRa,
Dalian, China) according to the manufacturer’s instruc-
tions. The results were normalized to the expression of
beta-actin. The primers used are shown in Additional
file 2: Table S1. For quantitative measurement of the
CD44 variable exons expressed, qRT-PCR was per-
formed using a CFX96 Real-Time system (Bio-Rad, CA,
USA) with the following cycling conditions: 95°C for 30
sec, followed by 40 cycles of 95°C for 5 sec and 60°C for
Table 1 Associations between the status of CD44 variants and CD44s and the categorical clinicopathological parameters of pancreatic carcinoma (n = 101)
Parameters CD44v2 CD44v3 CD44v4 CD44v5 CD44v6 CD44v7 CD44v8 CD44v9 CD44v10 CD44s
+ - + - + - + - + - + - + - + - + - + -
Gender
P-value 0.379 0.379 0.956 0.68 0.956 0.178 0.956 0.956 0.322 0.379
Male/Female 40/10 37/14 40/10 37/14 39/12 38/12 39/11 38/13 39/12 38/12 41/9 36/15 38/12 39/12 39/12 38/12 41/10 36/14 40/10 37/14
Age, years
P-value 0.875 0.551 0.551 0.777 0.777 0.551 0.551 0.777 0.47 0.551
<65/≥65 36/14 36/15 37/13 35/16 37/13 35/16 35/15 37/14 37/14 35/15 37/13 35/16 37/13 35/16 37/14 35/15 38/13 34/16 37/13 35/16
Tumor location
P-value 0.353 0.796 0.737 0.737 0.796 0.796 0.796 0.737 0.737 0.353
Head/Body,tail 42/8 46/5 44/6 44/7 45/6 43/7 43/7 45/6 44/7 44/6 44/6 44/7 44/6 44/7 45/6 43/7 45/6 43/7 42/8 46/5
Tumor size, cm
P-value 0.9 0.593 0.489 0.346 0.489 0.9 0.9 0.9 0.593 0.271
≤2/>2 19/31 20/31 18/32 21/30 18/33 21/29 17/33 22/29 18/33 21/29 19/31 20/31 19/31 20/31 20/31 19/31 21/30 18/32 22/28 17/34
Lymphatic invasion
P-value 0.625 0.197 0.055 0.197 0.02 0.09 0.09 0.02 0.129 0.474
Neg/Pos 27/23 30/21 25/25 32/19 24/27 33/17 25/25 32/19 23/28 34/16 24/26 33/18 24/26 33/18 23/28 34/16 25/26 32/18 30/20 27/24
Vascular invasion
P-value 0.006 0.408 0.408 0.702 0.951 0.408 0.951 0.702 0.951 0.203
Neg/Pos 30/20 43/8 38/12 35/16 35/16 38/12 37/13 36/15 37/14 36/14 38/12 35/16 36/14 37/14 36/15 37/13 37/14 36/14 39/11 34/17
Neural invasion
P-value 0.875 0.875 0.777 0.3 0.875 0.777 0.551 0.245 0.875 0.47
Neg/Pos 36/14 36/15 36/14 36/15 37/14 35/15 38/12 34/17 36/15 36/14 35/15 37/14 37/13 35/16 39/12 33/17 36/15 36/14 34/16 38/13
Duodenal invasion
P-value 0.295 0.583 0.653 0.653 0.295 0.295 0.653 0.583 0.961 0.147
Neg/Pos 38/12 43/8 39/11 42/9 40/11 41/9 41/9 40/11 43/8 38/12 38/12 43/8 41/9 40/11 42/9 39/11 41/10 40/10 43/7 38/13
Hepatic metastases
P-value 0.484 0.042 0.049 0.172 0.049 0.049 0.042 0.049 0.049 0.049
Neg/Pos 44/6 47/4 42/8 49/2 43/8 48/2 43/7 48/3 43/8 48/2 43/7 48/3 42/8 49/2 43/8 48/2 43/8 48/2 48/2 43/8
Differentiation
P-value 0.808 0.1 0.507 0.124 0.202 0.927 0.491 0.696 0.428 0.028
Poor 13 16 18 11 17 12 19 10 15 14 14 15 15 14 13 16 16 13 11 18
Middle 32 31 26 37 29 34 27 36 29 34 31 32 29 34 32 31 29 34 31 32














Table 1 Associations between the status of CD44 variants and CD44s and the categorical clinicopathological parameters of pancreatic carcinoma (n = 101)
(Continued)
Stage (UICC)
P-value 0.837 0.109 0.057 0.135 0.008 0.286 0.061 0.027 0.143 0.028
IA/IB 4/11 6/14 3/13 7/12 2/12 8/13 2/13 8/12 2/13 8/12 3/12 7/13 4/12 6/13 4/11 6/14 4/12 6/13 6/18 4/7
IIA/IIB 9/20 6/20 4/22 11/18 5/24 10/16 5/23 10/17 3/25 12/15 5/23 10/17 3/23 12/17 3/25 12/15 4/23 11/17 4/19 11/21
III/IV 0/6 0/5 0/8 0/3 0/8 0/3 0/7 0/4 0/8 0/3 0/7 0/4 0/8 0/3 0/8 0/3 0/8 0/3 0/3 0/8
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expressed relative to those of a normal pancreas sample
and were then converted to fold changes. The PCR
products were separated on a 2.0% agarose gel, stained
with ethidium bromide (EB) and photographed with a
video camera (Vilber Lourmat, Marne-la-Vallée, France).
The sizes of all of the qRT-PCR products for CD44v and
CD44s are referred to in Additional file 2: Table S1. All
experiments were performed in triplicate, and the means
of three values are presented.Calculating the optimized cut-off point for CD44v2-
CD44v10 and CD44s
As quantitative analysis of CD44v2-CD44v10 and CD44s
expression in pancreatic carcinoma is novel, no estab-
lished cut-off points are available. For this analysis, we
used two methods to select the cut-off point: (1) the log-
rank test, performed by testing the prognostic value at
each possible cut-off point (e.g., 25%, 50%, 75%) and
(2) Cox regression analysis, including all possible cut-off
points (e.g., 25%, 50%, 75%). We divided the samples
into two groups, according to the median and the 25th
and 75th percentiles. We found that the median cut-off
point gave a lower P-value than did the other points
using both the log-rank test and Cox regression analysis,
with a comparable hazard ratio (HR) for overall survival
(OS). Only CD44v6, CD44v9 and CD44s were signifi-
cantly associated with OS (data not shown), and only
those variants were used in the cut-off point analysis
(Additional file 3: Figure S2). Using the median cut-off
point, we defined a group with ‘low CD44’ (negative)
and a group with ‘high CD44’ (positive). All Chi-square
(χ2) analysis, Kaplan-Meier (KM) survival analysis and
Cox regression analysis were performed using data based
on the median cut-off point.Statistical analysis
All analyses were performed using SPSS 19.0 software
(IBM, Chicago, USA). The correlation between categor-
ical variables was evaluated using the χ2 test. Data were
analyzed using Student’s t-test if the involved compari-
son groups followed normal distributions; otherwise,
the nonparametric Mann–Whitney test was applied.
Univariate analysis was conducted by the KM method
(the log-rank test). Multivariate analysis was performed
using the stepwise Cox multivariate proportional haz-
ard regression model (forward, likelihood ratio), and
the values of variables not in the equation were picked
from step 1. P-values <0.05 were considered to be
statistically significant, and all statistical analysis was
completed under the guidance of experienced experts
from the Statistics Department of third military medical
university.Results
Increased expression of CD44v and decreased expression
of CD44s were associated with the invasion and
metastatic potential of PCa
To analyze the expression levels of all CD44 variants,
we first designed primers for each variant. Due to the
complexity of CD44 isoform expression, we hoped to
find a novel method for studying CD44, rather than
using previous methods of analyzing CD44 isoforms.
The primers for CD44v2-CDv10 were therefore de-
signed to be located in each exon, rather than in exons
1–5 and 16–20, as had been performed previously.
The sense primer (3′) for CD44s was located in exon
5, and the antisense primer (5′) spanned exons 5 through
16, producing only CD44s, as described by Konig, H [44]
(Additional file 1: Figure S1, Additional file 2: Table S1).
All products were verified by agarose electrophoresis
(Figure 1B).
We then detected the expression levels of all CD44
variants in the three pancreatic carcinoma cell lines.
Among the Aspc-1 (As), Cfpac-1 (Cf) and Panc-1 (Pa)
pancreatic carcinoma cell lines, the expression levels of
CD44v2-CD44v10 (CD44v), from highest to lowest, were
in As, Cf and Pa. Interestingly, the expression levels of
CD44s, from highest to lowest, were in Pa, Cf and As
(Figure 2C, D), which indicates that the pancreatic car-
cinoma cell lines expressed different levels of CD44v
and CD44s.
We next tested the cell invasion capabilities of these
three pancreatic carcinoma cell lines using transwell
assays. The As cell line showed the highest invasion
capacity; Cf, the median invasion capacity; and Pa, the
lowest invasion capacity (Figure 2A, B). These results
suggest that increased expression of CD44v or decreased
expression of CD44s is associated with the invasion po-
tential of the PCa cell lines.
To further explore the relationship between the ex-
pression of CD44 and PCa metastasis, we analyzed the
expression levels of CD44v and CD44s in five meta-
static pancreatic carcinoma samples (which included
two hepatic metastases, two lymphatic invasions and
one vascular invasion), five non-metastatic samples and
ten peritumoral tissue samples. As shown in Figure 1A,
when compared with peritumoral tissue, PCa showed
both increased CD44v expression and decreased CD44s
expression (CD44v5, v6, v9 and v10 and CD44s showed
significant differences). Moreover, higher expression of
CD44v and lower expression of CD44s were found in
metastatic samples compared with non-metastatic samples
(CD44v6 and CD44s showed significant differences).
These results are consistent with the observations noted
when analyzing the three cell lines, which suggests that
the expression of CD44v and CD44s is associated with
tumor metastasis.
Figure 1 Expression levels of CD44v and CD44s in clinical pancreatic carcinoma tissues. A The expression levels of CD44v and CD44s were
tested in metastatic tissues (n = 5), non-metastatic tissues (n = 5) and their corresponding peritumoral tissues (n = 10). B The PCR products of
tissues were confirmed by agarose gel electrophoresis. C The expression levels of CD44v6, CD44v9 and CD44s measured by real-time PCR were
associated with the clinical characteristics of pancreatic carcinoma (n = 101).
Figure 2 Invasion capacities and CD44 expression levels of Aspc-1, Cfpac-1 and Panc-1. A-B Tumor cell invasion activities were measured
using a transwell assay. Representative image fields of invasive cells on the membrane are shown. C-D Expression levels of CD44v and CD44s in
three PCa cell lines.
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poor prognosis in pancreatic carcinoma
To further investigate whether CD44v2-CD44v10 and
CD44s are involved pancreatic carcinoma metastasis,
we analyzed the relationship between the clinical char-
acteristics of pancreatic carcinoma patients and the
expression of CD44v2-CD44v10 and CD44s. As shown
in Table 1, CD44v6+ and CD44v9+ were significantly
correlated with lymph node metastasis (P = 0.02), liver
metastasis (P = 0.049) and TNM stage (P = 0.008 and
P = 0.027, respectively), and CD44s− was significantly
correlated with liver metastasis (P = 0.049), differenti-
ation (P = 0.028) and TNM stage (P = 0.028). However,
CD44v2-CD44v5+, CD44v7+, CD44v8+ and CD44v10+
were not correlated with any clinicopathological char-
acteristics of pancreatic carcinoma. We further applied
a nonparametric Mann–Whitney test to analyze the
relationships between the clinicopathological charac-
teristics and the expression of CD44v6, CD44v9 and
CD44s. As shown in Figure 1C, CD44v6+ and CD44v9+
were correlated with lymph node metastasis, liver me-
tastasis and TNM stage, and CD44s− was associated
with liver metastasis and TNM stage. These results indi-
cate that CD44v6+, CD44v9+ and CD44s− may be asso-
ciated with poor prognosis in pancreatic carcinoma
patients.Figure 3 KM survival curves for the OS of patients with pancreatic ca
CD44s (D), CD44v9/CD44s (E) and CD44v6/CD44v9 (F).CD44v6+, CD44v9+ and CD44s− are key factors that affect
the survival of pancreatic carcinoma patients
We further analyzed whether the expression levels of
CD44v2-CD44v10 and CD44s were associated with the
survival rate of patients with pancreatic carcinoma. KM
curve analysis showed that patients with CD44v6+ and
CD44v9+ had significantly low survival rates (P = 0.01
and P = 0.047, respectively). In contrast, patients with
CD44s− had significantly low survival rates (P = 0.032)
(Figure 3A-C). Patients with CD44v2-CD44v5+, CD44v7+,
CD44v8+ and CD44v10+ demonstrated no differences in
survival rate (data not shown). Interestingly, pancreatic car-
cinoma patients with tumors that were CD44v6+/CD44s−
or CD44v9+/CD44s− had a significantly lower survival
rate than did patients with tumors expressing CD44v6+,
CD44v9+ or CD44s− alone. However, CD44v6+/CD44v9+
did not further decrease the patients’ survival rate
(Figure 3D-F). These results suggest that CD44v6+,
CD44v9+ and CD44s− are key factors affecting the sur-
vival of pancreatic carcinoma patients.
CD44v6+/CD44s− expression was an independent risk
factor associated with the OS rate of pancreatic
carcinoma patients
We used univariate and multivariate analyses to identify
independent risk factors associated with the survival ratercinoma according to CD44v6 (A), CD44v9 (B), CD44s (C), CD44v6/
Table 2 Univariate analysis of prognostic factors in
pancreatic adenocarcinoma (n = 101)






< 65 53 12 20.0
≥65 22 13 20.2
Gender 0.793
Female 16 10 12.5
Male 59 12 22.5
Tumor size (cm) 0.230
≤2 28 12 28.0
>2 47 11 15.9
pN 0.002
Negative 39 14 28.2
Positive 36 10 10.8
Pv 0.045
Negative 55 12 26.1
Positive 20 10 5.0
Hepatic metastases 0.000
Negative 68 12 22.3
Positive 7 6 0
Differentiation 0.989
Poor 21 11 25.8
Moderate 49 12 17.7
Well 5 10 20.0
pStage (UICC) 0.000
I 24 16 33.3
II 44 11 15.9
III,IV 7 6 0
CD44v6 expression 0.010
Negative 35 14 28.5
Positive 40 10 13.0
CD44v9 expression 0.047
Negative 37 12 27.0
Positive 38 10 13.7
CD44s expression 0.032
Negative 40 10 12.5
Positive 35 14 29.6
CD44v6,v9 expression 0.014
Negative 40 13 27.3
Positive 35 10 12.0
CD44v6,s expression 0.000
Negative 53 13 29.0
Positive 22 7 0
Table 2 Univariate analysis of prognostic factors in
pancreatic adenocarcinoma (n = 101) (Continued)
CD 44v9,s expression 0.000
Negative 53 13 29.0
Positive 22 7 0
The bold values indicate P-values less than 0.05. pN pathological node stage,
pV pathological vessel status, pStage TNM stage (UICC), s CD44s.
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and 3, univariate analysis revealed that lymph node me-
tastasis (pN); vessel invasion (pV); hepatic metastases;
TNM stage; and individual or co-expression of CD44v6+,
CD44v9+ and CD44s− were risk factors that significantly
affected the survival of pancreatic carcinoma patients. How-
ever, multivariate analysis showed that only D44v6+/CD44s−
and pN were independent risk factors affecting the OS
of pancreatic carcinoma patients (P = 0.003 and P = 0.002,
respectively). Therefore, among all CD44 variants,
CD44v6+/CD44s− was an independent risk factor af-
fecting the OS rate of pancreatic carcinoma patients.
Discussion
CD44 has been studied for three decades, with hundreds
of papers devoted to cancer research, but no consensus
opinion on cancer progression has been reached until
now. Thousands of CD44 isoforms can be generated due
to alternative splicing, and each isoform may function
differently. Traditional methods for studying CD44 at
the mRNA level make it too difficult to distinguish
between splicing isoforms and to analyze clinical tissues.
In the present study, we designed primers specific for
each exon of CD44 variants and for the exons of CD44s.
We could therefore effectively distinguish each CD44
variant in pancreatic carcinoma tissue, rather than trying
to identify thousands of complicated CD44 isoforms. A
similar method was also applied in Slominski’s research
[45]. Although the CD44 variants were distinguished
only at mRNA level and protein-level validation of these
data is required, but there are no enough specific anti-
bodies to recognize each CD44 variant at present.
Therefore, this method is also effective and useful for
identifying CD44 splicing isoforms.
Many factors such as lymphatic vascular density,
vascular endothelial growth factors (VEGF) and CD44
are involved in PCa progression [46-48]. Our results
suggest that increased expression of CD44v and de-
creased expression of CD44s are associated with pan-
creatic carcinoma metastasis and progression. First, we
found that CD44v expression was increased and that
CD44s expression was decreased in pancreatic carcinoma
cell lines and in human tissue samples. Second, the indi-
vidual expression of CD44v and CD44s was associated
with invasion and metastasis in pancreatic carcinoma cell
Table 3 Multivariate analysis of the prognostic factors associated with survival in pancreatic adenocarcinoma (n = 101)
Independent factors Univariate P Multivariate P Hazard ratio 95% Confidence interval
Pn (Neg/Pos) 0.002 0.002 2.313 1.376-3.889
pv (Neg/Pos) 0.045 0.370 1.342 0.705-2.557
Hepatic metastases (Neg/Pos) 0.000 0.051 2.558 0.998-6.555
pStage (I/II/III, IV) 0.000 0.925 1.041 0.450-2.407
CD44v6 expression (Neg/Pos) 0.010 0.281 1.869 0.600-5.824
CD44v9 expression (Neg/Pos) 0.047 0.718 0.748 0.155-3.603
CD44s expression (Neg/Pos) 0.032 1.000 1.000 0.437-2.287
CD44v6,v9 expression (Neg/Pos) 0.014 0.809 0.809 0.146-4.486
CD44v6,s expression (Neg/Pos) 0.000 0.003 2.602 1.390-4.870
CD44v9,s expression (Neg/Pos) 0.000 0.810 0.808 0.142-4.587
The bold values indicate P-values less than 0.05 in multivariate analysis, pN pathological node stage, pV pathological vessel status, pStage TNM stage (UICC),
s CD44s, Neg negative, Pos positive.
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CD44v and CD44s may play different roles in pancreatic
carcinoma metastasis. These results are consistent with
the findings of previous studies, which suggested that
CD44v and CD44s function differently in pancreatic car-
cinoma than in other cancers [41,43,49].
CD44v6 and CD44v9 have been identified as markers
for tumor progression and metastasis in various cancers
[50-53]. However, no consensus has been reached re-
garding the role of CD44s. The results of the present
study indicate that CD44v6+, CD44v9+ and CD44s− may
affect the prognosis of pancreatic carcinoma. CD44v6+
and CD44v9+ were significantly correlated with lymph
node invasion, liver metastasis and TNM stage, and
CD44s- was correlated with liver metastasis, tumor differ-
entiation and TNM stage. CD44v2-CD44v5+, CD44v7+,
CD44v8+ and CD44v10+ were not correlated with any
clinicopathological characteristics of pancreatic carcinoma.
A nonparametric test showed similar results. Therefore,
in pancreatic carcinoma, CD44v6+, CD44v9+ and CD44s−
may be related to poor prognosis.
CD44 is a novel type of molecule that may be involved
in tumor growth, invasion and metastasis. A recent
study showed that the switch of CD44s to CD44v6 can
promote the development of a normal mammary gland
into carcinoma [54]. Furthermore, it has been shown
that CD44v6 and CD44v9 can increase invasion and me-
tastasis via cooperating with c-Met to activate the MEK
and Erk signaling pathways [55] and can increase antia-
poptotic ability via inhibiting Fas signaling [56]. In the
present study, we found that CD44v6+, CD44v9+ and
CD44s− significantly decreased the survival rate of pan-
creatic carcinoma patients. Additionally, patients with
PCa and co-expression of CD44v6 and CD44s or co-
expression of CD44v9 and CD44s had a significantly
lower survival rate in comparison with patients withexpression of CD44v6+, CD44v9+ or CD44s− alone. Fur-
thermore, CD44v6+/CD44s− was found to be an inde-
pendent risk factor.
Conclusions
In this study, we applied a specific method for testing
the expression of CD44v2-CD44v10 and CD44s in 101
pancreatic carcinoma tissues, and then further evalu-
ated their roles in pancreatic carcinoma metastasis and
prognosis using clinical survival analysis. We demon-
strated that among all CD44 variants, CD44v6+, CD44v9+
and CD44s− were significantly associated with the
metastasis and prognosis of pancreatic carcinoma. The
different expression patterns of CD44v and CD44s may
be useful markers for predicting the prognosis of pan-
creatic carcinoma.
Additional files
Additional file 1: Figure S1. Schematic of primers specific for CD44v
(A) and CD44s (B) (v2-v10 are abbreviations for CD44v2-CD44v10).
Additional file 2: Table S1. Sequences of the CD44v2-CD44v10, CD44s
and beta-actin PCR primers.
Additional file 3: Figure S2. Identification of cut-off points for CD44v6,
CD44v9 and CD44s. Population (n = 101) was divided into two groups
according to the median and the 25th and 75th percentiles. P-values and
HRs were calculated (Cox regression) for OS for each cut-off point.
Competing interests
The authors declare no conflict of interest.
Authors’ contributions
ZHL and XWL designed the study, ZHL and KC carried out the experiments
and drafted the manuscript, PJ and XZ participated in the statistical analysis.
All authors read and approved the final manuscript.
Acknowledgments
This work was supported by the Chongqing Natural Science Fund Project
(2012JB1032), the Project of the National Natural Science Fund (81272363,
30872497), the National 863 Project of China (No. 2012AA02A201), the
Li et al. Diagnostic Pathology 2014, 9:79 Page 10 of 11
http://www.diagnosticpathology.org/content/9/1/79National Basic Research Program of China (973 Program) (2010CB529400)
and the National Science and Technology Major Project of China
(2008ZX10002-026). We thank Dr. Yazhou Wu and Dr. Lin Liu (Statistics
Department, Military Preventive Medicine, Third Military Medical University)
for their statistical assistance.
Received: 17 December 2013 Accepted: 1 April 2014
Published: 8 April 2014References
1. Abel EV, Simeone DM: Biology and clinical applications of pancreatic
cancer stem cells. Gastroenterology 2013, 144:1241–1248.
2. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK,
Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin 2013,
63:318–348.
3. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, Aridome K,
Yokomine T, Natsugoe S, Aikou T, Takao S: Clinical significance of midkine
expression in pancreatic head carcinoma. Br J Cancer 2007, 97:405–411.
4. Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC:
A human lymphocyte homing receptor, the hermes antigen, is related to
cartilage proteoglycan core and link proteins. Cell 1989, 56:1063–1072.
5. Stamenkovic I, Amiot M, Pesando JM, Seed B: A lymphocyte molecule
implicated in lymph node homing is a member of the cartilage link
protein family. Cell 1989, 56:1057–1062.
6. Screaton GR, Bell MV, Bell JI, Jackson DG: The identification of a new
alternative exon with highly restricted tissue expression in transcripts
encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all
10 variable exons between mouse, human, and rat. J Biol Chem 1993,
268:12235–12238.
7. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic
structure of DNA encoding the lymphocyte homing receptor CD44
reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A
1992, 89:12160–12164.
8. Tolg C, Hofmann M, Herrlich P, Ponta H: Splicing choice from ten variant
exons establishes CD44 variability. Nucleic Acids Res 1993, 21:1225–1229.
9. Gallatin WM, Weissman IL, Butcher EC: A cell-surface molecule involved in
organ-specific homing of lymphocytes. Nature 1983, 304:30–34.
10. Haegel H, Dierich A, Ceredig R: CD44 in differentiated embryonic stem
cells: surface expression and transcripts encoding multiple variants.
Dev Immunol 1994, 3:239–246.
11. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M,
Lu Y, Chen Q: CD44 is of functional importance for colorectal cancer
stem cells. Clin Cancer Res 2008, 14:6751–6760.
12. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S,
Pierotti MA, Daidone MG: Isolation and in vitro propagation of
tumorigenic breast cancer cells with stem/progenitor cell properties.
Cancer Res 2005, 65:5506–5511.
13. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly
JG, Chandra D, Zhou J, Claypool K: Highly purified CD44+ prostate cancer
cells from xenograft human tumors are enriched in tumorigenic and
metastatic progenitor cells. Oncogene 2006, 25:1696–1708.
14. Haynes BF, Liao HX, Patton KL: The transmembrane hyaluronate receptor
(CD44): multiple functions, multiple forms. Cancer Cells 1991, 3:347–350.
15. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M,
Beppu T, Tamada M, Nagano O: CD44s regulates the TGF-beta-mediated
mesenchymal phenotype and is associated with poor prognosis in patients
with hepatocellular carcinoma. Cancer Res 2012, 72:3414–3423.
16. Ryu HS, Park SH, Lee KB, Shin E, Jang JJ: Expression of the Transmembrane
Glycoprotein CD44s Is Potentially an Independent Predictor of
Recurrence in Hepatocellular Carcinoma. Gut Liver 2011, 5:204–209.
17. Zhang J, Chang B, Liu J: CD44 standard form expression is correlated with
high-grade and advanced-stage ovarian carcinoma but not prognosis.
Hum Pathol 2013, 44:1882–1889.
18. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C:
CD44 splice isoform switching in human and mouse epithelium is
essential for epithelial-mesenchymal transition and breast cancer
progression. J Clin Invest 2011, 121:1064–1074.
19. Afify AM, Tate S, Durbin-Johnson B, Rocke DM, Konia T: Expression of
CD44s and CD44v6 in lung cancer and their correlation with prognostic
factors. Int J Biol Markers 2011, 26:50–57.20. Costa WH, Rocha RM, Cunha IW, Guimaraes GC, Zequi Sde C:
Immunohistochemical expression of CD44s in renal cell carcinoma lacks
independent prognostic significance. Int Braz J Urol 2012, 38:456–465.
21. Dome B, Somlai B, Ladanyi A, Fazekas K, Zoller M, Timar J: Expression of
CD44v3 splice variant is associated with the visceral metastatic
phenotype of human melanoma. Arch: Int J Oral Maxillofac Pathol 2001,
439:628–635.
22. Sun BS, Li Y, Zhang ZF, You J, Wang CL: Osteopontin combined With
CD44v6, a novel prognostic biomarker in non-small cell lung cancer
undergoing curative resection. Ann Thorac Surg 2013, 96:1943–1951.
23. Shi J, Zhou Z, Di W, Li N: Correlation of CD44v6 expression with ovarian
cancer progression and recurrence. BMC Cancer 2013, 13:182.
24. Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y,
Kurashige J, Miyamoto Y, Baba H: CD44v6 expression is related to
mesenchymal phenotype and poor prognosis in patients with colorectal
cancer. Oncol Rep 2013, 29:1570–1578.
25. Li XD, Ji M, Wu J, Jiang JT, Wu CP: Clinical significance of CD44 variants
expression in colorectal cancer. Tumori 2013, 99:88–92.
26. Hsieh HF, Yu JC, Ho LI, Chiu SC, Harn HJ: Molecular studies into the role of
CD44 variants in metastasis in gastric cancer. Mol Pathol 1999, 52:25–28.
27. Gotte M, Yip GW: Heparanase, hyaluronan, and CD44 in cancers: a breast
carcinoma perspective. Cancer Res 2006, 66:10233–10237.
28. Takahashi K: Restoration of CD44S in non-small cell lung cancer cells
enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer
2003, 41:145–153.
29. Montgomery E, Abraham SC, Fisher C, Deasel MR, Amr SS, Sheikh SS, House
M, Lilliemoe K, Choti M, Brock M: CD44 loss in gastric stromal tumors as a
prognostic marker. Am J Surg Pathol 2004, 28:168–177.
30. Lazari P, Poulias H, Gakiopoulou H, Thomopoulou GH, Barbatis C, Lazaris AC:
Differential immunohistochemical expression of CD44s, E-cadherin and
beta-catenin among hyperplastic and neoplastic lesions of the prostate
gland. Urol Int 2013, 90:109–116.
31. Gunia S, May M, Koch S, Dietel M, Erbersdobler A: Expression of CD44s in
incidental prostate cancer is more strongly associated with Gleason
scores on subsequent radical prostatectomies than conventional
prognostic parameters. Pathobiology 2009, 76:286–292.
32. Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC:
Downregulation of BRG-1 repressed expression of CD44s in cervical
neuroendocrine carcinoma and adenocarcinoma. Mod Pathol 2006,
19:1570–1577.
33. Jeffrey S, Ross M: Decreased CD44 standard form expression correlates
with prognostic variables in ovarian carcinomas. Am J Clin Pathol 2001,
116:122–128.
34. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD: CD44v3
levels in primary cutaneous melanoma are predictive of prognosis:
assessment by the use of tissue microarray. Int J Cancer 2006,
118:1460–1464.
35. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Tohnai I,
Ueda M, Kimata K: CD44 variant exon 6 expressions in colon cancer
assessed by quantitative analysis using real time reverse transcriptase-
polymerase chain reaction. Oncol Rep 2003, 10:1919–1924.
36. Zalewski B: Levels of v5 and v6 CD44 splice variants in serum of patients
with colorectal cancer are not correlated with pT stage,
histopathological grade of malignancy and clinical features. World J
Gastroenterol 2004, 10:583–585.
37. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N,
Sahin A, Gilcrease MZ: CD44 expression is associated with increased
survival in node-negative invasive breast carcinoma. Clin Cancer Res 2005,
11:3309–3314.
38. Foekens JA, Dall P, Klijn JG, Skroch-Angel P, Claassen CJ, Look MP, Ponta H,
Van Putten WL, Herrlich P, Henzen-Logmans SC: Prognostic value of CD44
variant expression in primary breast cancer. Int J Cancer 1999, 84:209–215.
39. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Holzel F, Maass H,
Gunthert U: CD44 isoforms correlate with cellular differentiation but not
with prognosis in human breast cancer. Cancer Res 1995, 55:5424–5433.
40. Tsukuda H, Matsumura Y, Inoue T, Kobayashi Y, Ookawa K, Aoki T, Nebiki H,
Yamazaki O, Kondo H, Kakizoe T: Diagnostic application of CD44 variant
expression in pancreatic juice for detection of pancreatic neoplasm.
Anticancer Res 2001, 21:2175–2183.
41. Rall CJ, Rustgi AK: CD44 isoform expression in primary and metastatic
pancreatic adenocarcinoma. Cancer Res 1995, 55:1831–1835.
Li et al. Diagnostic Pathology 2014, 9:79 Page 11 of 11
http://www.diagnosticpathology.org/content/9/1/7942. Tomaszewska R: [Morphologic, morphometric and immunohistochemical
studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Folia Med Cracov 1999, 40:101–141.
43. Gotoda T, Matsumura Y, Kondo H, Saitoh D, Shimada Y, Kosuge T, Kanai Y,
Kakizoe T: Expression of CD44 variants and its association with survival in
pancreatic cancer. Jpn J Cancer Res 1998, 89:1033–1040.
44. Konig H, Moll J, Ponta H, Herrlich P: Trans-acting factors regulate the
expression of CD44 splice variants. EMBO J 1996, 15:4030–4039.
45. Slominski AT, Raso-Barnett L, Banky B, Barbai T, Becsagh P, Timar J, Raso E:
Demonstration of a melanoma-specific CD44 alternative splicing pattern
that remains qualitatively stable, but shows quantitative changes during
tumour progression. PLoS One 2013, 8:e53883.
46. Sullu Y, Gun S, Atmaca S, Karagoz F, Kandemir B: Poor prognostic
clinicopathologic features correlate with VEGF expression but not with
PTEN expression in squamous cell carcinoma of the larynx. Diagn Pathol
2010, 5:35.
47. Zhou G, Chiu D, Qin D, Niu L, Cai J, He L, Tan D, Xu K: Expression of
CD44v6 and integrin-beta1 for the prognosis evaluation of pancreatic
cancer patients after cryosurgery. Diagn Pathol 2013, 8:146.
48. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M,
Ikeda T, Asaba R, Yagi H: CD44 variant regulates redox status in cancer
cells by stabilizing the xCT subunit of system xc(-) and thereby
promotes tumor growth. Cancer Cell 2011, 19:387–400.
49. Abetamann V, Kern HF, Elsasser HP: Differential expression of the hyaluronan
receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer
Res 1996, 2:1607–1618.
50. Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H, Tahara E: Expression
of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and
adenocarcinomas: relation to the proliferation and progression. Int J
Oncol 1998, 12:1253–1258.
51. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E:
Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer
1998, 79:127–132.
52. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA: Prostate cancer invasion
is influenced more by expression of a CD44 isoform including variant 9
than by Muc18. Lab Invest 2004, 84:894–907.
53. Goi T, Koneri K, Katayama K, Hirose K, Yamaguchi A: Evaluation of
clinicopathological factors and the correlation between the adhesion
molecule CD44 variant 9 expression and pulmonary metastases from
colorectal cancers. Int Surg 2002, 87:130–136.
54. Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF: Expression of CD44s,
CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-
carcinoma in breast. Appl Immunohistochem Mol Morphol 2008, 16:121–127.
55. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H: CD44 is
required for two consecutive steps in HGF/c-Met signaling. Genes Dev
2002, 16:3074–3086.
56. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U: A novel
antiapoptotic mechanism based on interference of Fas signaling by
CD44 variant isoforms. Cell Death Differ 2006, 13:465–477.
doi:10.1186/1746-1596-9-79
Cite this article as: Li et al.: CD44v/CD44s expression patterns are
associated with the survival of pancreatic carcinoma patients. Diagnostic
Pathology 2014 9:79.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
